XROMI

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Lithuania, Poland, United Kingdom

Active ingredients

The drug XROMI contains one active pharmaceutical ingredient (API):

1 Hydroxycarbamide UNII X6Q56QN5QC - HYDROXYUREA

One of the mechanisms by which hydroxycarbamide acts is the elevation of foetal haemoglobin (HbF) concentrations in sickle cell patients. In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein. Read about Hydroxycarbamide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
XROMI Oral solution	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX05	Hydroxycarbamide	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1799039
Country: FR	Base de données publique des médicaments	Identifier(s): 66462922
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 375695
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1088131
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100423186